| Literature DB >> 27330969 |
D M Torta1, T Costa2, E Luda3, M G Barisone4, P Palmisano4, S Duca5, G Geminiani2, F Cauda2.
Abstract
Medication-overuse headache (MOH) is a secondary form of headache related to the overuse of triptans, analgesics and other acute headache medications. It is believed that MOH and substance addiction share some similar pathophysiological mechanisms. In this study we examined the whole brain resting state functional connectivity of the dorsal and ventral striatum in 30 patients (15 MOH and 15 non-MOH patients) to investigate if classification algorithms can successfully discriminate between MOH and non-MOH patients on the basis of the spatial pattern of resting state functional connectivity of the dorsal and ventral striatal region of interest. Our results indicated that both nucleus accumbens and dorsal rostral putamen functional connectivity could discriminate between MOH and non-MOH patients, thereby providing possible support to two interpretations. First, that MOH patients show altered reward functionality in line with drug abusers (alterations in functional connectivity of the nucleus accumbens). Second, that MOH patients show inability to break habitual behavior (alterations in functional connectivity of the dorsal striatum). In conclusion, our data showed that MOH patients were characterized by an altered functional connectivity of motivational circuits at rest. These differences could permit the blind discrimination between the two conditions using classification algorithms. Considered overall, our findings might contribute to the development of novel diagnostic measures.Entities:
Mesh:
Year: 2016 PMID: 27330969 PMCID: PMC4900511 DOI: 10.1016/j.nicl.2016.05.007
Source DB: PubMed Journal: Neuroimage Clin ISSN: 2213-1582 Impact factor: 4.881
Clinical characteristics of the sample.
| Patient | MOH | Age | History of headache or MOH (years) | Frequency of headache (days in a month) | Overused (or used) medication |
|---|---|---|---|---|---|
| 1 | Yes | 36 | 0.5 | 12 | Triptans + Analgesics |
| 2 | Yes | 60 | 4 | 10 | Triptans |
| 3 | Yes | 48 | 10 | 10 | Triptans + Analgesics |
| 4 | Yes | 37 | 3 | 15 | Combination Analgesics |
| 5 | Yes | 63 | 2 | 20 | Analgesics |
| 6 | Yes | 30 | 2 | 15 | Analgesics + Combination analgesics |
| 7 | Yes | 36 | 0.5 | 30 | Analgesics |
| 8 | Yes | 49 | 4 | 15 | Triptans |
| 9 | Yes | 45 | 7 | 20 | Combination analgesics |
| 10 | Yes | 43 | 1 | 18 | Analgesics |
| 11 | Yes | 55 | 5 | 30 | Triptans |
| 12 | Yes | 40 | 3 | 12 | Combination analgesics + opioids |
| 13 | Yes | 49 | 0.6 | 12 | Triptans |
| 14 | Yes | 36 | 10 | 14 | Triptans + FANS |
| 15 | Yes | 30 | 1 | 15 | Triptans |
| 16 | No | 22 | 14 | 15 | Analgesics |
| 17 | No | 37 | 0.4 | 30 | – |
| 18 | No | 51 | 0.6 | 15 | Analgesics |
| 19 | No | 54 | 40 | 4 | – |
| 20 | No | 27 | 20 | 7 | Analgesics |
| 21 | No | 30 | 11 | 6 | Triptans |
| 22 | No | 28 | 18 | 8 | Analgesics |
| 23 | No | 52 | 34 | 13 | Non-steroidal anti-inflammatory drugs |
| 24 | No | 32 | 0.5 | 20 | Triptans |
| 25 | No | 19 | 9 | 20 | – |
| 26 | No | 47 | 20 | 15 | Analgesics |
| 27 | No | 36 | 10 | 12 | Non-steroidal anti-inflammatory drugs |
| 28 | No | 45 | 2 | 20 | Analgesics |
| 29 | No | 39 | 15 | 2 | Analgesics |
| 30 | No | 44 | 20 | 3 | Combination analgesics |
Fig. 1Regions of interest (ROIs) used in the study. Functional connectivity was calculated from the nucleus accumbens (NAcc), left panel, the dorsal caudal putamen (DCP), and the dorsal rostral putamen (DRP). Coordinates of the seed are provided in the bottom left square of each figure.
Psychological questionnaires, individual level. MIDAS (Migraine Disability Assessment), BDI (Beck Depression Inventory), STAI (State Trait Anxiety Inventory), SF-12 (The 12-Item Short Form Survey), PCS (Physical Component Summary), MCS (Mental Component Summary).
| Psychological questionnaires | |||||||
|---|---|---|---|---|---|---|---|
| Patient | MOH | MIDAS | BDI | STAI Y1 | STAI Y2 | SF-12 | |
| PCS | MCS | ||||||
| 1 | Yes | 0 | 6 | 29 | 30 | 47.7 | 57.46 |
| 2 | Yes | 18 | 8 | 29 | 40 | 42.52 | 46.75 |
| 3 | Yes | 120 | 8 | 58 | 55 | 35.63 | 29.14 |
| 4 | Yes | 32 | 17 | 45 | 49 | 37.94 | 36.34 |
| 5 | Yes | 40 | 8 | 41 | 34 | 42.57 | 40.89 |
| 6 | Yes | 27 | 7 | 41 | 42 | 44.3 | 29.62 |
| 7 | Yes | 36 | 19 | 59 | 51 | 33.04 | 37.03 |
| 8 | Yes | 54 | 8 | 29 | 35 | 40.33 | 51.11 |
| 9 | Yes | 54 | 21 | 68 | 57 | 44.56 | 23.69 |
| 10 | Yes | 60 | 5 | 33 | 42 | 32.77 | 47.23 |
| 11 | Yes | 20 | 0 | 32 | 22 | 48.8 | 53.49 |
| 12 | Yes | 4 | 3 | 34 | 33 | 49.21 | 54.49 |
| 13 | Yes | 29 | 5 | 54 | 42 | 30.04 | 48.66 |
| 14 | Yes | 6 | 11 | 42 | 46 | 41.58 | 37.14 |
| 15 | Yes | 31 | 10 | 36 | 43 | 44.01 | 51.09 |
| 16 | No | 22 | 16 | 51 | 55 | 46.4 | 23.64 |
| 17 | No | 16 | 11 | 56 | 51 | 56.58 | 60.76 |
| 18 | No | 90 | 13 | 44 | 52 | 31.6 | 33.54 |
| 19 | No | 30 | 5 | 32 | 37 | 32.19 | 52.35 |
| 20 | No | 48 | 18 | 44 | 52 | 44.86 | 35.75 |
| 21 | No | 29 | 5 | 35 | 39 | 42.54 | 57.33 |
| 22 | No | 5 | 3 | 33 | 26 | 47.81 | 54.32 |
| 23 | No | 7 | 11 | 30 | 37 | 47.78 | 44.47 |
| 24 | No | 88 | 7 | 43 | 63 | 53.48 | 48.26 |
| 25 | No | 0 | 7 | 25 | 28 | 40.8 | 55.18 |
| 26 | No | 6 | 4 | 32 | 36 | 48.64 | 53.65 |
| 27 | No | 27 | 7 | 30 | 45 | 49.51 | 52.58 |
| 28 | No | 5 | 5 | 30 | 32 | 43.21 | 47.11 |
| 29 | No | 44 | 0 | 31 | 28 | 36.19 | 52.56 |
| 30 | No | 26 | 13 | 30 | 46 | 31.13 | 39.13 |
Neuropsychological profile, individual levels (WCST, Wisconsin Card Sorting Test).
| Neuropsychological questionnaires | |||||
|---|---|---|---|---|---|
| Patient | MOH | Phonemic fluency | Semantic fluency | WCST | Tower of London |
| 1 | Yes | 28 | 15.75 | 33 | 27.75 |
| 2 | Yes | 38 | 19.5 | 9 | 23.25 |
| 3 | Yes | 25 | 18.25 | 11 | 25.5 |
| 4 | Yes | 45 | 21.25 | 9 | 30.25 |
| 5 | Yes | 7 | 15.5 | 5 | 17.75 |
| 6 | Yes | 33 | 16.5 | 29 | 26.5 |
| 7 | Yes | 39 | 19.25 | 4 | 25.25 |
| 8 | Yes | 30 | 13.5 | 17 | 23.25 |
| 9 | Yes | 30 | 22.25 | 8 | 25.5 |
| 10 | Yes | 35 | 24.25 | 22 | 27.5 |
| 11 | Yes | 26 | 20 | 12 | 28.75 |
| 12 | Yes | 39 | 23.25 | 10 | 29.25 |
| 13 | Yes | 34 | 19 | 13 | 20.25 |
| 14 | Yes | 29 | 12.00 | 23 | 28.25 |
| 15 | Yes | 34 | 15 | 8 | 28.25 |
| 16 | No | 31 | 13.5 | 9 | 23.25 |
| 17 | No | 25 | 13.5 | 23 | 21.25 |
| 18 | No | 36 | 27.75 | 10 | 26.25 |
| 19 | No | 30 | 13.5 | 20 | 27.25 |
| 20 | No | 46 | 19.75 | 18 | 21.25 |
| 21 | No | 31 | 12.25 | 8 | 16 |
| 22 | No | 29 | 19 | 17 | 30 |
| 23 | No | 37 | 17.5 | 25 | 30 |
| 24 | No | 32 | 14.25 | 19 | 22.5 |
| 25 | No | 26 | 17 | 9 | 26.25 |
| 26 | No | 39 | 23.5 | 9 | 19.75 |
| 27 | No | 22 | 12.25 | 12 | 24.25 |
| 28 | No | 27 | 19.75 | 25 | 24.25 |
| 29 | No | 28 | 19.75 | 4 | 29.25 |
| 30 | No | 37 | 20 | 3 | 30.5 |
Psychological questionnaires, group level (mean ± standard deviation).
| Group | MIDAS (mean ± sd) | BDI | STAI Y1 | STAI Y2 | SF-12 | |
|---|---|---|---|---|---|---|
| PCS | MCS | |||||
| MOH | 35.4 ± 29.5 | 9 ± 5.8 | 42 ± 12.4 | 41.4 ± 9.5 | 41 ± 5.9 | 42.9 ± 10.3 |
| Non-MOH | 29.5 ± 28 | 8.3 ± 5.1 | 36.4 ± 8.9 | 41.8 ± 11.2 | 43.5 ± 7.8 | 47.3 ± 10.2 |
Neuropsychological profile, group level (mean ± standard deviation) (WCST, Wisconsin Card Sorting Test).
| Group | Phonemic fluency (mean ± sd) | Semantic fluency | WCST | Tower of London |
|---|---|---|---|---|
| MOH | 31.4 ± 8.7 | 18.3 ± 3.5 | 14.2 ± 8.7 | 25.8 ± 3.4 |
| Non-MOH | 31.7 ± 6.2 | 17.5 ± 4.4 | 14 ± 7.3 | 24.8 ± 4.2 |
Fig. 2Resting state functional connectivity of the nucleus accumbens (NAcc), dorsal caudal putamen (DCP) and dorsal rostral putamen (DRP). Areas in red represent positive correlations, those in blue represent negative correlations among voxels. This figure shows functional connectivity of all groups together, separate figures per group can be found in the supplementary material. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
Fig. 3Results of the MVPA for the nucleus accumbens (NAcc) (left) and the dorsal rostral putamen (DRP) (right). Yellow areas show greater predictive values for patients with medication overuse (MOH). (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)